|
Wednesday, September 12, 2018
9 a.m. to 4 p.m. EST
FDA Headquarters
10903 New Hampshire Avenue
Silver Spring, Maryland 20993
Public Meeting Attendance information here.
Register here by Wed., Sept. 5, 2018 for webcast and in-person attendance
FDA is holding a public hearing on Wed., Sept. 12 to get feedback from stakeholders on the Agency’s six-part Predictive Toxicology Roadmap for integrating cutting-edge predictive toxicology methods into safety and risk assessments of its products. Among other recommendations, the roadmap calls for FDA research to identify data gaps to support intramural and extramural research to ensure that the most promising technologies are developed, validated, and integrated into the product pipeline.
New methods like organs-on-a-chip and mathematical modeling are being developed for toxicity testing that could potentially help us move products to market faster and prevent products with increased toxicological risk from reaching the market. FDA is looking to hear from its stakeholders on how to foster the development and evaluation of these emerging toxicological technologies and incorporate them into regulatory review, as applicable. For more information, visit FDA’s website.
No hay comentarios:
Publicar un comentario